MedPath

The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve

Not Applicable
Not yet recruiting
Conditions
Diminished Ovarian Reserve
Interventions
Dietary Supplement: "KB-120" small molecular nutrient and vitamin E
Dietary Supplement: Vitamin E
Registration Number
NCT06081257
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Brief Summary

"KB-120" small molecular nutrient is a structural multi-molecular natural nutrient with different components. It is produced from strains and natural plant culture-medium that can be used in food and is designed according to different efficacy of different products by multi-stage solid-liquid complex fermentation technology. The functional directions of the product series involved are: immune function damage repair, intestinal villi damage repair, sperm development machinery damage repair, ovarian function damage repair, liver function damage repair, sleep disorder function damage repair, etc.Previous studies have shown that "KB-120" has good clinical effects on improving the number and function of male germ cells.Luanbao "KB-120" is a compound plant health drink specially for women. This study intends to give "KB-120" small molecule nutrients as nutritional supplement intervention in female patients with ovarian dysfunction, and observe its influence on endocrine function, ovarian reserve function and fertility in patients with ovarian dysfunction.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
80
Inclusion Criteria
  1. Patients with low ovarian function: FSH ≥10IU/L or AMH ≤1.1ng/ml.
  2. The age at the time of signing the informed consent is 20-40 years old (including 20 and 40 years old) and has not been menopausal;
  3. Be willing to sign written informed consent and comply with the study protocol
Exclusion Criteria
  1. Patients with severe anemia or malignant tumor; Lactation or pregnancy;
  2. Eating disorders or anorexia;
  3. Taking hormone drugs or participating in any other study.
  4. There are factors that researchers believe cannot be included in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
experimental group"KB-120" small molecular nutrient and vitamin E"KB-120" small molecule nutrients, taken orally once a day in one bag (30ml), and vitamin E100mg taken orally 2 times a day for a total of 3 menstrual cycles
experimental groupVitamin E"KB-120" small molecule nutrients, taken orally once a day in one bag (30ml), and vitamin E100mg taken orally 2 times a day for a total of 3 menstrual cycles
control groupVitamin EVitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
Primary Outcome Measures
NameTimeMethod
Concentration of serum FSH 1on the 3rd day of the 2nd menstruation(each cycle is 23-30 days)

Blood samples were collected on the 3rd day of the 2nd menstruation

Concentration of serum FSH 2on the 3rd day of the 4th menstruation(each cycle is 23-30 days)

Blood samples were collected on the 3rd day of the 4th menstruation

Concentration of serum AMH 1on the 3rd day of the 2nd menstruation(each cycle is 23-30 days)

Blood samples were collected on the 3rd day of the 2nd menstruation

Concentration of serum AMH 2on the 3rd day of the 4th menstruation(each cycle is 23-30 days)

Blood samples were collected on the 3rd day of the 4th menstruation

Secondary Outcome Measures
NameTimeMethod
The number of days of the menstrual cycle 3At the end of Cycle 3(each cycle is 23-30 days)

The number of days of the menstrual cycle 3

The number of days of the menstrual cycle 1At the end of Cycle 1 (each cycle is 23-30 days)

The number of days of the menstrual cycle 1

The diameter of dominant follicle and the number of days required for ovulation 1At the end of Cycle 1 (each cycle is 23-30 days)

The follicle development of patients was monitored by ultrasound during the 1st menstrual cycle, and the monitoring interval was determined according to the clinical experience of clinicians and the development of patients' follicles

pregnancy rate for women trying to get pregnant 1At the end of Cycle 1 (each cycle is 23-30 days)

pregnancy rate for women trying to get pregnant

pregnancy rate for women trying to get pregnant 2At the end of Cycle 3 (each cycle is 23-30 days)

pregnancy rate for women trying to get pregnant

The diameter of dominant follicle and the number of days required for ovulation 2At the end of Cycle 3 (each cycle is 23-30 days)

The follicle development of patients was monitored by ultrasound during the 3rd menstrual cycle, and the monitoring interval was determined according to the clinical experience of clinicians and the development of patients' follicles

© Copyright 2025. All Rights Reserved by MedPath